In 2017, Byrd et al. found that engineering of primary human T cells by 2nd generation (CD28.CD3‐) and 3rd generation (CD28.41BB.CD3‐) TEM8‐specific CAR molecules derived from the scFv of the TEM8 antibody could effectively kill TEM8+ TNBC tumour cell lines such as Hs578T, MDA‐MB‐231, MDA‐MB‐436 and MDA‐MB‐468 and human breast tumour endothelial line HC 6020 and murine tumour endothelial cell lines 2H11 and bEND.3.187. This evidence concerns the gene CD28 and neoplasm.